Previous 10 | Next 10 |
Summary Utilizing the ongoing market sell-off, Soros Fund Management, also known as the "Soros Fund", doubled down on some of the household names within the technology sector ahead of the recent. The fund seems to have significantly increased its efforts to pursue attractive merge...
Soros' 13F portfolio value decreased from $6.57B to $5.62B this quarter. The number of positions decreased from 273 to 271. Soros increased Alphabet, Amazon.com, and Salesforce.com while reducing Rivian and Liberty Broadband. They also increased the leveraged long positions on the...
Pfizer is buying Biohaven for $148.50 and 0.5 share of new-Biohaven. New-Biohaven should be worth at least between $3.50 and $8.50. The spread to the cash value is miniscule. The spread to merger consideration values is significant. This deal seems highly unlikely to fail ...
Form 13F filings show fund managers' top arbitrage stocks. Top M&A stocks of the 30 funds I follow. Activision Blizzard this quarter's top stock. It was an interesting few months for merger arb. In early June, spreads blew out as Thoma Bravo cut the price for its deal wi...
On May 18, I wrote the first of three articles stating that healthcare stocks, and specifically biopharmaceuticals, had likely bottomed. XBI was at 68 and IBB 114. Both XBI and IBB have increased since then. I viewed the valuations a few months ago as being compelling in several insta...
Teva Pharmaceutical's revenue was $3,786 million in Q2 2022, up 3.4% QoQ. The company's total debt continues to decline quarter on quarter and stands at $22,453 million at the end of Q2 2022. Teva Pharmaceutical has made progress in resolving opioid crisis lawsuits, reaching an ag...
The biotech industry for the first half of the year had seen better six-month periods in the past, but the situation appears to have changed beginning in July. From Jan. 1 to June 20, 2022, the SPDR S&P Biotech ETF ( XBI ) and iShares Nasdaq Biotechnology ETF ( IBB ) had...
Biohaven Pharmaceuticals press release ( NYSE: BHVN ): Q2 Non-GAAP EPS of -$3.82 misses by $1.57 . Revenue of $194M (+108.8% Y/Y) misses by $16.6M . The Company remains on track to meet full year 2022 net product sales guidance of $825 - $900 million. For...
Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments PR Newswire Antitrust approvals have been granted by the relevant governing authorities, including the Federal Trade Commission ("FTC"), with respect to the previously annou...
SMID cap growth stocks have entered bear market territory, pressured by significant multiple compression from higher interest rates and unfolding economic deceleration. The Strategy underperformed in a difficult market, with declines most pronounced among several long-term holdings in...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
2024-05-29 12:00:07 ET Brian Skorney from Robert W. Baird issued a price target of $58.00 for BHVN on 2024-05-29 09:57:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $30.31. The overall price target consensus is at $...
2024-05-29 11:00:21 ET Leonid Timashev from RBC Capital issued a price target of $59.00 for BHVN on 2024-05-29 09:14:00. The adjusted price target was set to $59.00. At the time of the announcement, BHVN was trading at $28.69. The overall price target consensus is at $23...